Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.95 - phosphoglycerate dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
6,7-dihydropteridine reductase deficiency
Cerebral folate deficiency.
Adenocarcinoma
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
One carbon metabolism in human lung cancer.
PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Adenocarcinoma of Lung
Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum.
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Adenoma
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Adrenal Gland Neoplasms
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Adrenocortical Adenoma
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Adrenocortical Carcinoma
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Alveolar Bone Loss
Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase.
Amebiasis
Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.
Anemia
On the phenotypic spectrum of serine biosynthesis defects.
aromatic-l-amino-acid decarboxylase deficiency
Cerebral folate deficiency.
Arthrogryposis
Neu-Laxova syndrome presenting prenatally with increased nuchal translucency and cystic hygroma: The utility of exome sequencing in deciphering the diagnosis.
Asthma
Fatal cerebral edema associated with serine deficiency in CSF.
Brain Diseases
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Two new cases of serine deficiency disorders treated with l-serine.
Brain Ischemia
Cellular origin and regulation of D- and L-serine in in vitro and in vivo models of cerebral ischemia.
Brain Neoplasms
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Breast Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase.
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Bioinformatics analysis of the serine and glycine pathway in cancer cells.
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.
LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-?1 and downregulating PHGDH.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
PHGDH as a mechanism for resistance in metabolically-driven cancers.
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Resurgence of serine: an often neglected but indispensable amino Acid.
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox.
Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.
Carcinogenesis
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis.
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.
Genetically-defined metabolic reprogramming in cancer.
Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity.
Carcinoma
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma.
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Expression of Glucose Metabolism-Related Proteins in Adrenal Neoplasms.
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2?-Targeting Therapy for Renal Cell Carcinoma.
Carcinoma, Ductal
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Carcinoma, Embryonal
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Carcinoma, Hepatocellular
Enzymic imbalance in serine metabolism in rat hepatomas.
Role of cysteine in the dietary control of the expression of 3-phosphoglycerate dehydrogenase in rat liver.
The modulation of serine metabolism in hepatoma 3924A during different phases of cellular proliferation in culture.
Carcinoma, Non-Small-Cell Lung
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Carcinoma, Renal Cell
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2?-Targeting Therapy for Renal Cell Carcinoma.
Carcinoma, Squamous Cell
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Colitis
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer.
Colonic Neoplasms
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Colorectal Neoplasms
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
Epilepsy
Phosphoglycerate dehydrogenase (PHGDH) deficiency without epilepsy mimicking primary microcephaly.
Fatty Liver
Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease.
Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption.
Gastritis
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Glioma
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Serine-dependent redox homeostasis regulates glioblastoma cell survival.
Glucose Intolerance
Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice.
Hepatitis B, Chronic
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hepatitis C, Chronic
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hepatitis, Autoimmune
Detection of D-3-phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation.
[Cloning and expression of 3-phosphoglycerate dehydrogenase gene and its correlative antibodies in diagnosis of autoimmune hepatitis]
Hyperglycinemia, Nonketotic
Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism.
Ichthyosis
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
Kearns-Sayre Syndrome
Cerebral folate deficiency.
Keloid
Upregulation of the NNP-1 (novel nuclear protein-1, D21S2056E) gene in keloid tissue determined by cDNA microarray and in situ hybridization.
Kidney Neoplasms
Kidney cancer: PHGDH is key for targeting HIF in RCC.
Leukemia
High Fructose Drives the Serine Synthesis Pathway in Acute Myeloid Leukemic Cells.
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth.
Liver Diseases
Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease.
Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption.
Lung Neoplasms
Bioinformatics analysis of the serine and glycine pathway in cancer cells.
Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
One carbon metabolism in human lung cancer.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Lymphatic Metastasis
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Lymphoma
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
Malaria
A Cas9 transgenic Plasmodium yoelii parasite for efficient gene editing.
Melanoma
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Cancer's sweet tooth for serine.
Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Increased PHGDH expression promotes aberrant melanin accumulation.
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.
PHGDH amplification and altered glucose metabolism in human melanoma.
PHGDH as a mechanism for resistance in metabolically-driven cancers.
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
The PHGDH enigma: Do cancer cells only need serine or also a redox modulator?
Microcephaly
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
Inactivation of the 3-phosphoglycerate dehydrogenase gene in mice: changes in gene expression and associated regulatory networks resulting from serine deficiency.
Infantile Serine Biosynthesis Defect Due to Phosphoglycerate Dehydrogenase Deficiency: Variability in Phenotype and Treatment Response, Novel Mutations, and Diagnostic Challenges
Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.
Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH.
On the phenotypic spectrum of serine biosynthesis defects.
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Phosphoglycerate dehydrogenase (PHGDH) deficiency without epilepsy mimicking primary microcephaly.
Treatment with amino acids in serine deficiency disorders.
Two new cases of serine deficiency disorders treated with l-serine.
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
Micrognathism
Neu-Laxova syndrome presenting prenatally with increased nuchal translucency and cystic hygroma: The utility of exome sequencing in deciphering the diagnosis.
Multiple Acyl Coenzyme A Dehydrogenase Deficiency
Characterization of ETFDH and PHGDH Mutations in a Patient with Mild Glutaric Aciduria Type II and Serine Deficiency.
Multiple Myeloma
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Targeting phosphoglycerate dehydrogenase in multiple myeloma.
Myocardial Infarction
DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures.
Nasopharyngeal Carcinoma
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Nasopharyngitis
EBV-miR-BART1 is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma.
Neoplasm Metastasis
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
?-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).
A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism.
An epitope tag alters phosphoglycerate dehydrogenase structure and impairs ability to support cell proliferation.
Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation.
Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.
Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.
Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.
Bisphosphoglycerate mutase controls serine pathway flux via 3-phosphoglycerate.
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
Cancer's sweet tooth for serine.
Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Control of nutrient stress-induced metabolic reprogramming by PKC? in tumorigenesis.
Correction for Mullarky et al., Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
Coupling between d-3-phosphoglycerate dehydrogenase and d-2-hydroxyglutarate dehydrogenase drives bacterial l-serine synthesis.
Dimerization of PHGDH via the catalytic unit is essential for its enzymatic function.
Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors.
Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy.
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs).
Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma.
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma.
Expression of serine and glycine-related enzymes in phyllodes tumor.
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.
Genetically-defined metabolic reprogramming in cancer.
Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase.
Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy.
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype.
Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer.
Increased PHGDH expression promotes aberrant melanin accumulation.
Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.
Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition.
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma.
Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis.
Nucleotide sequence and differential expression of the human 3-phosphoglycerate dehydrogenase gene.
p73 regulates serine biosynthesis in cancer.
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
PHGDH amplification and altered glucose metabolism in human melanoma.
PHGDH as a mechanism for resistance in metabolically-driven cancers.
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
PHGDH supports liver ceramide synthesis and sustains lipid homeostasis.
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015-2020.
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Phosphoglycerate dehydrogenase: potential therapeutic target and putative metabolic oncogene.
Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Protein interactome of the deamidase phosphoribosylformylglycinamidine synthetase (PFAS) by LC-MS/MS.
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Resurgence of serine: an often neglected but indispensable amino Acid.
Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression.
Serine Metabolism Regulates YAP Activity Through USP7 in Colon Cancer.
Serine restriction alters sphingolipid diversity to constrain tumour growth.
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox.
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
Shift from stochastic to spatially-ordered expression of serine-glycine synthesis enzymes in 3D microtumors.
Structure-Activity Relationships (SARs) of ?-Ketothioamides as Inhibitors of Phosphoglycerate Dehydrogenase (PHGDH).
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.
The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.
The PHGDH enigma: Do cancer cells only need serine or also a redox modulator?
The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer.
Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.
Neuroblastoma
Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Neurotoxicity Syndromes
Fatal cerebral edema associated with serine deficiency in CSF.
Obesity
Deletion of PHGDH in adipocytes improves glucose intolerance in diet-induced obese mice.
DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures.
Target identification of the novel antiobesity agent tungstate in adipose tissue from obese rats.
Optic Atrophy
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Osteoporosis
Tanshinone prevents alveolar bone loss in ovariectomized osteoporosis rats by up-regulating phosphoglycerate dehydrogenase.
Osteosarcoma
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma.
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma.
Ovarian Neoplasms
In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach.
PHGDH Is Upregulated at Translational Level and Implicated in Platin-Resistant in Ovarian Cancer Cells.
Proteomic alterations of fibroblasts induced by ovarian cancer cells reveal potential cancer targets.
Pancreatic Neoplasms
Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH.
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer.
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Parathyroid Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Parkinson Disease
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Phenylketonurias
Cerebral folate deficiency.
phosphoglycerate dehydrogenase deficiency
3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis.
3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis.
3-phosphoglycerate dehydrogenase deficiency: description of two new cases in Tunisia and review of the literature.
A Serine Synthesis Defect Presenting With a Charcot-Marie-Tooth-Like Polyneuropathy.
Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.
Cerebral folate deficiency.
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
Continuing education in neurometabolic disorders--serine deficiency disorders.
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Effect of selectively knocking down key metabolic genes in Müller glia on photoreceptor health.
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
Fatal cerebral edema associated with serine deficiency in CSF.
Genetic disorders of gamma-aminobutyric acid, glycine, and serine as causes of epilepsy.
Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency.
Infantile Serine Biosynthesis Defect Due to Phosphoglycerate Dehydrogenase Deficiency: Variability in Phenotype and Treatment Response, Novel Mutations, and Diagnostic Challenges
Neurotransmitters in 3-phosphoglycerate dehydrogenase deficiency.
Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics.
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency.
Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency.
Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism.
Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells.
Treatment with amino acids in serine deficiency disorders.
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
[Genetic and phenotypic analysis of a patient with phosphogylcerate dehydrogenase deficiency].
phosphoserine phosphatase deficiency
3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis.
Continuing education in neurometabolic disorders--serine deficiency disorders.
Treatment with amino acids in serine deficiency disorders.
Phyllodes Tumor
Expression of serine and glycine-related enzymes in phyllodes tumor.
Polyneuropathies
A Serine Synthesis Defect Presenting With a Charcot-Marie-Tooth-Like Polyneuropathy.
Pulmonary Fibrosis
Inhibition of PHGDH Attenuates Bleomycin-induced Pulmonary Fibrosis.
Retinal Diseases
Serine biosynthesis defect due to haploinsufficiency of PHGDH causes retinal disease.
Rett Syndrome
Cerebral folate deficiency.
ring-type e3 ubiquitin transferase deficiency
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Sarcoma
Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma.
Sarcoma, Ewing
Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
PHGDH as a mechanism for resistance in metabolically-driven cancers.
Seizures
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency.
Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids.
Expanding the clinical spectrum of 3-phosphoglycerate dehydrogenase deficiency.
Genetic disorders of gamma-aminobutyric acid, glycine, and serine as causes of epilepsy.
Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis.
Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings.
Treatment with amino acids in serine deficiency disorders.
V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme.
Small Cell Lung Carcinoma
One carbon metabolism in human lung cancer.
Spasms, Infantile
3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome.
Early onset West syndrome with cerebral hypomyelination and reduced cerebral white matter.
Starvation
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.
Role of cysteine in the dietary control of the expression of 3-phosphoglycerate dehydrogenase in rat liver.
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
Stillbirth
On the phenotypic spectrum of serine biosynthesis defects.
Stomach Neoplasms
Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.
Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.
Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer.
Strabismus
3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures.
Thyroid Cancer, Papillary
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Thyroid Carcinoma, Anaplastic
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.
Thyroid Neoplasms
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer.
Triple Negative Breast Neoplasms
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox.
Tuberculosis
A Novel Mechanism for Substrate Inhibition in Mycobacterium tuberculosis D-3-Phosphoglycerate Dehydrogenase.
Crystal structure of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase: extreme asymmetry in a tetramer of identical subunits.
D-3-Phosphoglycerate dehydrogenase from Mycobacterium tuberculosis is a link between the Escherichia coli and mammalian enzymes.
Determinants of substrate specificity in D-3-phosphoglycerate dehydrogenase. Conversion of the M. tuberculosis enzyme from one that does not use ?-ketoglutarate as a substrate to one that does.
Kinetic Evidence of a Noncatalytic Substrate Binding Site That Regulates Activity in Legionella pneumophilal-Serine Dehydratase.
Kinetic, mutagenic, and structural homology analysis of L-serine dehydratase from Legionella pneumophila.
Regulation of Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase by phosphate-modulated quaternary structure dynamics and a potential role for polyphosphate in enzyme regulation.
Role of the Anion-Binding Site in Catalysis and Regulation of Mycobacterium tuberculosis d-3-Phosphoglycerate Dehydrogenase.
Structural analysis of substrate and effector binding in Mycobacterium tuberculosis D-3-phosphoglycerate dehydrogenase.
Structure of L-serine dehydratase from Legionella pneumophila: novel use of the C-terminal cysteine as an intrinsic competitive inhibitor.
Urinary Bladder Neoplasms
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Uterine Cervical Neoplasms
3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment.
Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
High Expression of PHGDH Predicts Poor Prognosis in Non-Small Cell Lung Cancer.
Varicocele
Down regulating PHGDH affects the lactate production of sertoli cells in varicocele.
Virus Diseases
Serine metabolism antagonizes antiviral innate immunity by preventing ATP6V0d2-mediated YAP lysosomal degradation.